The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 2: Psoriasis

May 17, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Ustekinumab (Stelara):20 injection

Drug class: Monoclonal antibody, inter­leukin (IL) 12/23) inhibitor

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
Explore This Issue
May 2019

Warnings & Precautions

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Serious infections have occurred. Do not start ustekinumab during any clinically important active infection. If a serious infection or clinically significant infection develops, consider discontinuing ustekinumab until the infection resolves.
  • Theoretical infection risk: Serious infections from mycobacteria, salmonella and Bacillus Calmette-Guerin (BCG) vaccinations have occurred in patients genetically deficient in IL-12/IL-23. Diagnostic tests for these infections should be considered as dictated by clinical circumstances.
  • Evaluate patients for TB prior to initiating treatment with ustekinumab. Initiate treatment of latent TB before administering ustekinumab.
  • Ustekinumab may increase malignancy risk. The safety of using ustekinumab in patients with a history of, or a known, malignancy has not been evaluated.
  • Anaphylaxis or other clinically significant hypersensitivity reactions may occur.
  • Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in one case. If suspected, treat promptly and discontinue ustekinumab.
  • Cases of noninfectious, interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported during postmarketing ustekinumab use. If diagnosis is confirmed, discontinue ustekinumab and initiate appropriate treatment.

Dosage & Administration

Subcutaneous Adult Dosage Regimen:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • For patients weighing 100 kg or less, the recommended dose is 45 mg initially and four weeks later, followed by 45 mg every 12 weeks.
  • For patients weighing more than 100 kg, the recommended dose is 90 mg initially and four weeks later, followed by 90 mg every 12 weeks.

Subcutaneous Adolescent Dosage Regimen:

Administer the drug subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.

The recommended dose for adolescents (12–17 years old) is based on body weight.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Less than 60 kg: the recommended dose is 0.75 mg/kg.
  • 60 kg to 100 kg: the recommended dose is 45 mg.
  • More than 100 kg: the recommended dose is 90 mg.

Commentary: The FDA approved uste­kinumab for moderate to severe plaque psoriasis treatment in adults based on data from two randomized controlled studies, and in adolescents based on data from one randomized controlled study. The PASI 75 results were both clinically and statistically significant at the end of the study. The most common adverse reactions (≥3%) are arthralgias and nausea.

Brodalumab (Siliq):21 injection

Drug class: Monoclonal antibody, IL-17 receptor antagonist (IL-17-RA)

Boxed warning: Suicidal ideation and behavior

  • Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab.
  • Prior to prescribing, weigh potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior.
  • Patients with new or worsening suicidal thoughts and behavior should be referred to a mental health professional.
  • Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.
  • Brodalumab is available only through a restricted program called the SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program.

Warnings & Precautions

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, apremilast, brodalumab, Certolizumab Pegol, etanercept, guselkumab, guttate psoriasis, infliximab, inverse psoriasis, ixekizumab, Psoriatic Arthritis, psoriatic erythroderma, pustular psoriasis, Rheumatic Drugs at a Glance, secukinumab, tildrakizumab, ustekinumab, vulgar psoriasisIssue: May 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)